Anticancer low cost, Novartis loses appeal in India Local industry will be able ‘to produce the medicine

The Indian Supreme Court has rejected the appeal of the Swiss pharmaceutical company Novartis on the patent of an anti-tumor. The CNN IBN television reported. The judges decided that the local industry has the right to produce the drug Glivec as a generic drug low cost to protect the right to health of the population.

The long-awaited verdict comes after a seven-year legal battle waged by the giant Swiss to gain the respect of the property laws’ intellectual. As motivation, the Supreme Court said that the Glivec” and not ‘an innovative product because”’ uses a molecule already ‘known and therefore not part of the criteria for the” inventions”. According to various Indian associations for the defense of human rights is a defeat of” Big Pharma” and confirmation of India as” poor” pharmacy world.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s